Xeris Biopharma HoldingsXERS
XERS
About: Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).
Employees: 394
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
355% more call options, than puts
Call options by funds: $2.44M | Put options by funds: $537K
229% more first-time investments, than exits
New positions opened: 56 | Existing positions closed: 17
114% more capital invested
Capital invested by funds: $223M [Q4 2024] → $477M (+$254M) [Q1 2025]
87% more repeat investments, than reductions
Existing positions increased: 73 | Existing positions reduced: 39
50% more funds holding in top 10
Funds holding in top 10: 2 [Q4 2024] → 3 (+1) [Q1 2025]
23% more funds holding
Funds holding: 162 [Q4 2024] → 199 (+37) [Q1 2025]
12.3% more ownership
Funds ownership: 44.08% [Q4 2024] → 56.39% (+12.3%) [Q1 2025]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$7
61%
upside
Avg. target
$7
61%
upside
High target
$7
61%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
Oppenheimer Leland Gershell | 61%upside $7 | Outperform Maintained | 9 May 2025 |
Financial journalist opinion
Neutral
Business Wire
1 week ago
Xeris Unveils Strategy for Long-Term Growth and Value Creation at 2025 Analyst & Investor Day
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, will host its first-ever Analyst and Investor Day today to showcase its strategy for sustainable growth and value creation. “We have built a strong foundation through innovation and a relentless commitment to improving patient lives. We will showcase how these achi.
Neutral
Business Wire
3 weeks ago
Xeris Announces Details for Analyst & Investor Day
CHICAGO--(BUSINESS WIRE)--Xeris Announces Details for Analyst & Investor Day.
Neutral
Seeking Alpha
1 month ago
Xeris Biopharma Holdings, Inc. (XERS) Q1 2025 Earnings Call Transcript
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS ) Q1 2025 Results Conference Call May 8, 2025 8:30 AM ET Company Participants Allison Wey - SVP of IR, Corporate Communications John Shannon - CEO Steve Pieper - CFO Conference Call Participants David Amsellem - Piper Sandler Eason Lee - Leerink Partners Jason Dorr - Oppenheimer Chase Knickerbocker - Craig-Hallum Operator Good morning. Thank you for attending today's Xeris Biopharma First Quarter 2025 Results Conference Call.
Negative
Zacks Investment Research
1 month ago
Xeris Biopharma (XERS) Reports Q1 Loss, Tops Revenue Estimates
Xeris Biopharma (XERS) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to loss of $0.14 per share a year ago.
Neutral
Business Wire
1 month ago
Xeris Biopharma Reports Record First Quarter 2025 Financial Results
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the first quarter ended March 31, 2025, and updated its fiscal 2025 total revenue guidance. “We're very pleased with our strong start to the year, delivering another quarter of outstanding revenue growth,” said John Shannon, Xe.
Negative
Seeking Alpha
1 month ago
Xeris Biopharma Holdings: Looking For More Growth In Q1 Earnings
Xeris Biopharma Holdings, Inc. has shown consistent double-digit growth and is expected to continue this trend, with Q1 earnings projected to drive the share price higher. Key metrics to watch include Gvoke and Recorlev revenues, EPS, adjusted EBITDA, and cash flow, as these will determine Xeris's path to profitability. Risks include potential underperformance in product revenue, rising SG&A expenses, and any delays in pipeline programs like XP-8121.
Neutral
Business Wire
1 month ago
Xeris Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025.
Neutral
Business Wire
2 months ago
Xeris Announces Changes to Its Board of Directors
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced changes to its board of directors. Ricki Fairley has resigned from the board in light of other commitments, effective immediately. The Board of Directors has appointed James Brady as a new director of Xeris' board to fill the vacancy. In addition.
Positive
Zacks Investment Research
2 months ago
Strength Seen in Xeris Biopharma (XERS): Can Its 5.6% Jump Turn into More Strength?
Xeris Biopharma (XERS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Neutral
Business Wire
2 months ago
Xeris Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke VialDx™ (glucagon) for Use as a Diagnostic Aid
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that its supplemental new drug application (sNDA) of Gvoke VialDx™ has received U.S Food and Drug Administration (FDA) approval for use as a diagnostic aid during radiologic examinations to temporarily inhibit movement of the gastrointestinal tra.
Charts implemented using Lightweight Charts™